Australasian Severe Asthma Registry
The Australasian Severe Asthma Network (ASAN) is a multicentre clinical research network that:
- collects and reports on data from people with severe asthma,
- facilitates clinical research in this population, and
- seeks to improve clinical practice for this condition.
The Australasian Severe Asthma Registry (ASAR) is a clinical quality registry, according to the Australian Government requirements. The ASAR (formally SAWD) is a multicentre cross-sectional study of the characteristics of severe asthma, based around asthma phenotypes, and a prospective cohort study of the outcomes and future risks of phenotypes of severe asthma. The linked research register which was developed to enable individuals with severe asthma to be contacted regarding participation in future studies has now been incorporated into ASAR.
The ASAR enrols eligible patients who are prospectively followed for at least 10 years. Data is collected using a secure online database. The information collected includes non-identifying demographic details, clinical data and patient-reported outcomes.
The ASAR platform encompasses a consistent and well characterised population. This platform also allows for additional modules to be applied as new research studies when the need arises. A specific question, concept or enquiry into the population which will involve extensive data collection will warrant establishment of an additional module for the eligible population. This module will add on to the existing platform in order to streamline data collection and utilise existing resources. Modules may be active for defined time periods or be continuous upon introduction.
One of such modules on ASAR is the Australian Benralizumab Registry (ABR). The ABR was developed to collect and report on data from people with severe refractory eosinophilic asthma who receive benralizumab:
- as part of the PBS subsidised benralizumab treatment cycle, and the Pharmaceutical Benefits Scheme (PBS) Section 100 Special Authority Program,
- who receive benralizumab for severe refractory eosinophilic asthma outside of the PBS restrictions.
Patients enrolled in the ABR are assessed for eligibility at registration and followed up prospectively for at least 2 years- data collection every 6 months.
If you are interested in being involved as a site, please contact:
Ms Laura Mitchell
ASAR Project Officer
P: 02 9222 6200